Pfizer (PFE)
25.41
+0.38 (1.52%)
NYSE· Last Trade: Aug 5th, 2:31 AM EDT
Looking for the most active stocks in the S&P500 index on Tuesday?chartmill.com
Via Chartmill · August 4, 2026
Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.
Via Benzinga · August 4, 2026
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt
Via MarketBeat · August 4, 2026
Dow rises 1.35% with technology sector leading market gains. Pfizer beats Q2 earnings expectations. Oil down 4.2%, gold up 0.8%, European markets higher.
Via Benzinga · August 4, 2026
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15...
Via StockStory · August 4, 2026
Pfizer (NYSE:PFE) Beats Q2 Expectations and Raises 2026 Revenue Guidancechartmill.com
Via Chartmill · August 4, 2026
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.
Via Investor's Business Daily · August 4, 2026
Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings reported and upbeat sales guidance issued.
Via Benzinga · August 4, 2026
Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.
Via Benzinga · August 4, 2026
The stock's yield is more than six times the S&P 500 average.
Via The Motley Fool · August 3, 2026
Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.
Via Benzinga · August 3, 2026
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Pfizer beat analysts’ rev...
Via StockStory · August 2, 2026
Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.
Via The Motley Fool · August 1, 2026
There is more to this stock than meets the eye.
Via The Motley Fool · July 31, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP diluted earnings per share rose 11% to $14.29, while non-GAAP net income reached $1.5 billion.
Chief
Via MarketBeat · July 30, 2026
Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center owner to raise elements of its full-year outlook.
Chief Executive Officer Lisa Palmer said the company
Via MarketBeat · July 30, 2026
Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.
Via Benzinga · July 30, 2026
AbbVie still looks like a compelling buy at its all-time high.
Via The Motley Fool · July 29, 2026
According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to
Via Talk Markets · July 29, 2026
Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.
Via Benzinga · July 27, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...
Via StockStory · July 26, 2026
Far from "yield traps," these high-yield dividend stocks represent good value at current prices.
Via The Motley Fool · July 26, 2026
Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?
Via The Motley Fool · July 25, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via StockStory · July 24, 2026
Could it become as successful in this niche as it was in the coronavirus vaccine market?
Via The Motley Fool · July 23, 2026